Great summary of minimal residual disease by
@max_diehn

@Stanford
at #AACR26. In local therapy setting: ctDNA most sensitive tool, tumor-informed assays now insurance-covered for many cancers. Next frontier -> ultrasensitive assays (1 in 10⁶!), interventional trials, & ctDNA